Robert Whitfield MD (speaker) warns that GLP-1 weight-loss drugs (e.g., Ozempic) can preferentially reduce facial fat—more so with newer, more effective formulations—while sparing muscle. He argues this causes premature facial aging ("Ozempic face") and predicts increased future demand for cosmetic interventions among younger patients (30s–50s) whose facial structure is altered by rapid fat loss.
That's why Ozempic face is such a problem. So this, none of this stuff is new, right? So if you're going to take a GLP1 and the new ones coming are going to be much more effective than the ones they have currently, what does that mean? So they'll, they'll whack just fat, not muscle, at a higher rate. And what's the consequence? So the thing that you don't want to do. Yeah, of course. Is ruin your facial fat. And that's why Ozempic face is such a problem. Personally, you know, I'm at. I'm on the back half of my career. If I was a young plastic surgeon, I would be thinking of, how can I help somebody in their 30s, 40s, 50s, who's taking GLP1s and really burning their facial fat? Because eventually they're going to come in because you're causing premature aging of your face. It looks horrible. Because if you take the structure of your face. And we used to always have guidance in our clinics by our mentors and they said if you're planning to lose five to ten pounds, your facial aesthetics will change.
